Treatment: Special conditions: Metabolic syndrome: Obesity and the hypertension connection

Journal of the American Society of Hypertension

Volumn 9, Issue 2, 2015, Pages 156-159

  Reisin, Efrain ^a   Owen, Jonathan ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRALLY ACTING ALPHA 2 AGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEPTIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ARTICLE; BLOOD VOLUME; CARDIOVASCULAR FUNCTION; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIPOTOXICITY; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; COMPLICATION; DISEASE MANAGEMENT; PATHOPHYSIOLOGY;

DISEASE MANAGEMENT; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY;

EID: 84924426982     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.12.015     Document Type: Article

References (15)

1. R. Zhang, and E. Reisin Obesity hypertension: the effect on cardiovascular and renal systems Am J Hypertens 13 2000 1308 1314
2. J.E. Neter, B.C. Stam, F.J. Kok, D.E. Grobbee, and J.M. Geleijnse Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials Hypertension 42 2003 878 884
3. S.P. Bagby Obesity initiated metabolic syndrome: a recipe for chronic kidney disease? J Am Soc Nephrol 5 2004 2775 2791
4. H. Gill, M. Mugo, A. Whaley-Connell, C. Stump, and J.R. Sowers The key role of insulin resistance in the cardiometabolic-syndrome Am J Med Sci 330 2005 290 294
5. K. Rahmouni, M.L.G. Conera, W.G. Haynes, and A.L. Mark Obesity-associated hypertension: new insights into mechanisms Hypertension 45 2005 9 14
6. J. Redon, R. Cifkora, S. Laurent, P. Nilsson, K. Warkiewicz, S. Eddine on behalf of the Scientific Council of the Europe Society of Hypertension The metabolic syndrome in hypertension: European Society of Hypertension position statement J Hypertens 26 2008 1891 1900
7. J.T. Wright Jr., S. Harris-Haywood, S. Pressel, J. Barzilay, C. Baimbridge, and C.J. Bareis Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 168 2008 207 217
8. Y.E. Bogaert, and S. Linas The role of obesity in the pathogenesis of hypertension Nat Clin Pract Nephrol 5 2009 101 111
9. E. Reisin, and A.V. Jack Obesity and hypertension: mechanisms, cardio-renal consequences and therapeutic approaches E.D. Frohlich, Medical Clinic of North America 2009 WB Saunders/Elsevier Publishing Inc 733 751
10. K. Sharma The link between obesity and albuminuria: adiponectin and podocyte dysfunction Kidney Int 76 2009 145 148
11. T. Fujita Mineralcorticoid receptors: salt-sensitive hypertension and metabolic syndrome Hypertension 55 2010 813 818
12. P. Deedwania Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers J Clin Hypertens 13 2011 52 59
13. L. Landsberg, L.J. Aronne, L.J. Beilin, V. Burke, L.I. Igel, and D. Lloyd-Jones Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment J Clin Hypertens 15 2013 14 33
14. K. Rahmouni Obesity-associated hypertension: recent progress in deciphering the pathogenesis Hypertension 64 2014 215 221
15. E. Reisin, J.W. Graves, J.M. Yamal, J.I. Barzilay, S.L. Pressel, P.T. Einhorn ALLHAT Collaborative Research Group Blood Pressure Control and Cardiovascular Outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT J Hypertens 32 2014 1503 1513